Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Senzime AB ( (SE:SEZI) ) has issued an announcement.
Senzime AB held an extraordinary general meeting where shareholders unanimously approved a directed share issue, allowing Adam Dahlberg to subscribe for up to 700,000 new shares at SEK 4.60 each. This decision will increase the company’s share capital by a maximum of SEK 87,500, potentially impacting its financial structure and market positioning.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is widely used for neuromuscular transmission monitoring during surgery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
YTD Price Performance: -7.09%
Average Trading Volume: 326,030
Current Market Cap: SEK799.8M
For detailed information about SEZI stock, go to TipRanks’ Stock Analysis page.